Results 141 to 150 of about 760 (154)

Pharmacokinetics and Tolerability of Intravenous Sulbactam-Durlobactam with Imipenem-Cilastatin in Hospitalized Adults with Complicated Urinary Tract Infections, Including Acute Pyelonephritis

Antimicrobial Agents and Chemotherapy, 2020
Roman Fomkin, Alita Miller, Krassimir Yanev   +2 more
exaly  

Sulbactam/Durlobactam

Clinical Therapeutics
openaire   +2 more sources

In Vitro Activity of Sulbactam-Durlobactam against Acinetobacter baumannii- calcoaceticus Complex Isolates Collected Globally in 2016 and 2017

Antimicrobial Agents and Chemotherapy, 2020
Samir Moussa, Alita Miller, Meredith A Hackel   +2 more
exaly  

Reviving β-lactams for Mycobacterium abscessus: the emerging role of durlobactam

Clinical Microbiology and Infection
Chengcheng Wang, Zhiyong Zong
openaire   +1 more source

Sulbactam Sodium and Durlobactam Sodium

openaire   +1 more source

Beyond resistance: assessing sulbactam-durlobactam’s role in today’s clinical landscape

Expert Review of Anti-infective Therapy
openaire   +2 more sources

Sulbactam–durlobactam: a β-lactam/β-lactamase inhibitor combination targeting Acinetobacter baumannii

Future Microbiology
Navaneeth Narayanan, John O'Donnell, John Mills   +2 more
exaly  

In vitro antibacterial activity of sulbactam-durlobactam in combination with other antimicrobial agents against Acinetobacter baumannii-calcoaceticus complex

Diagnostic Microbiology and Infectious Disease
Patricia Bradford, Nicole Carter, Alita Miller   +2 more
exaly  

Comparative in vitro activity of sulbactam with avibactam or durlobactam against carbapenem-resistant Acinetobacter baumannii

JAC-Antimicrobial Resistance
Yohei Doi, Ryan Shields, Marissa P Griffith   +2 more
exaly  

Sulbactam-durlobactam susceptibility test method development and quality control ranges for MIC and disk diffusion tests

Journal of Clinical Microbiology
Patricia Bradford, Nicole Carter, Alita Miller   +2 more
exaly